title: Antimicrobial development in the era of emerging resistance.
abstract: Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.
authors: Department of Microbiology, School of Medicine, Avda de Madrid 11, E-18012 Granada, Spain.
authors: Antonio
authors: A
authors: Sorlozano
authors: Cristina
authors: C
authors: Carrasco
authors: Jose
authors: J
authors: Cabeza
authors: Enrique
authors: E
authors: Villegas
authors: Jose
authors: J
authors: Gutierrez
mesh_terms: D000617:Aminoglycosides / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects; D002511:Cephalosporins / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D017277:Drug Approval; D024881:Drug Resistance, Bacterial; D006020:Glycopeptides / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000077427:Lipoglycopeptides; D011743:Pyrimidines / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D017193:Skin Diseases, Viral / Q000188:drug therapy*; D017334:Teicoplanin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D047090:beta-Lactams / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D011743:Pyrimidines; D017334:Teicoplanin; D047090:beta-Lactams; C486448:iclaprim; C443755:ceftobiprole; C469289:dalbavancin; C107057:fropenem; C100708:oritavancin; D014640:Vancomycin; C487637:telavancin